To read the full story, subscribe or sign in.

Yuhan-Sorrento’s cancer-focused Immuneoncia targets Kosdaq IPO

April 17, 2024

Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.

BioWorld Financings Cancer Immuno-oncology IPO Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for April 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

mRNA-based vaccine is immunogenic, protective in Lyme disease

BioWorld Science

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Alzheon’s lead candidate misses a phase III in early Alzheimer’s

BioWorld

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long...